Navigation Links
Insmed Retains RBC Capital Markets as Strategic Financial Advisor
Date:7/14/2008

a meeting with the FDA to discuss potentially initiating a Phase III clinical trial program for INS-19. The Company also intends to initiate human bioequivalence clinical studies for INS-20 in the fourth quarter of 2008, with data expected in the first quarter of 2009. Insmed has several other FOB products which are currently at an earlier stage of cell line development and product characterisation.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, strategic alternatives, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that strategic alternatives may never be consummated, product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow-on biologics market may be unsuccessful, our common stock coul
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Insmed to Appeal Delisting Notification From Nasdaq
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
6. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
8. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
11. Insmed to Present at CBI Follow-On Biologics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... GEA Niro Soavi the leader in ... the PandaPLUS 2000, which is ideal for new applications ... cell disruption . This compact laboratory homogenizer is the ... food, food additives and ingredients as well as for ...
(Date:1/22/2015)... January 22, 2015 Crystal Diagnostics (CDx) Xpress ... it has received AOAC-PTM Certifications for the six non-O157 Shiga ... O145; collectively referred to as STEC or the “Big-6”) as ... forming unit (cfu) per 325 g of raw ground beef ...
(Date:1/22/2015)... 2015 Selexis SA, a serial innovation ... Banks (RCBs) used for drug discovery to commercial manufacturing, ... include Next-Generation Sequencing (NGS) data packages. The ... manufacturing by ensuring the integrity of the gene, validation ...
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision medicine ... to enable the broad use of genomic, imaging and other ... appointment of Michelle Munson , CEO of Aspera, an ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 "We ...
Breaking Biology Technology:GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2
... Alimentary Health Ltd.,(Alimentary Health), the development stage specialty ... use of probiotics in the,treatment of Irritable Bowel ... Alimentary Health probiotic technology marketed as,Bifantis(R), is the ... in IBS symptoms. Alimentary Health is a ...
... Bioponic,Phytoceuticals, Inc. (OTC: BPYT) ("Bioponic"), an ... serving the Complementary,Alternative Medicine (CAM) and nutraceutical ... Sales and Marketing of Southern California as ... including the states,of California, Washington, Nevada, Arizona, ...
... Investor Conference, November 8, Features ... Mid-cap Public Growth Companies Renowned Investment Banker and ... Stelios Papadopoulos, PhD Provides ... Biotechnology,Council,s ninth annual MASS Opportunities Investor Conference, New,England,s largest ...
Cached Biology Technology:Recent Study Confirms Alimentary Health's Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome 2Recent Study Confirms Alimentary Health's Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome 3Recent Study Confirms Alimentary Health's Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome 4Bioponic Phytoceuticals to Roll Out Multiple Products to 1,000 Major Health Food Stores in the Western United States 22007 Massachusetts Biotechnology Council MASS Opportunities Investment Conference Showcases Leading Growth Companies 22007 Massachusetts Biotechnology Council MASS Opportunities Investment Conference Showcases Leading Growth Companies 3
(Date:12/17/2014)... Dec. 16, 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this market is ... Chemical sensors help in recording of patient data for ...
(Date:12/11/2014)... 09, 2014 Research and Markets , ... ) has announced the addition of the "Biometrics ... offering. One major trend emerging in ... in technology, it is important to upgrade biometric solutions ...
(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global leader ... series of digital telemetry implants to meet the ... part of the PhysioTel™ Digital platform, was designed ... data when incorporating functional endpoints into repeat-dose toxicology ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... Nguyen has been elected as a fellow of ... the national organization,s Council on Basic Cardiovascular Sciences., ... Arlington in 2005, specializes in cellular engineering. Her ... stem cell therapies., Liping Tang, interim chairman of ...
... (Nov. 20, 2013) - When invasive species move into new ... that make them sick. But new research from evolutionary biologists ... in the immune system may help house sparrows, one of ... In research published this week in Proceedings of the ...
... Bone grafts, which are used to treat head injuries ... scientists are reporting progress toward a new hormone therapy ... study, which was conducted on mice, appears in the ... Gazit at Cedars-Sinai Medical Center, Edward Schwarz from Rochester ...
Cached Biology News:USF researchers show invasive sparrows immune cells sharpen as they spread 2
... reported in heart tissues, and is ... culture conditions. Treatment of cells ... of TIMP-4 in some cell types, ... often require concentration of cell culture ...
PI/RNase Staining Buffer Solution , 100 ml Consult technical datasheet for details....
Selenoprotein P Purified Anti-Mouse clone 35, Isotype Mouse IgG 2b , 50 µg Consult technical datasheet for details....
Anti-Mouse Reticular Fibroblast, Purified (Clone ER-TR7) (rat IgG2a)...
Biology Products: